Why PSA Prostate Screening Is a Shared Decision

The short answer

PSA prostate screening is a shared decision because the evidence supports neither a firm yes nor a firm no. The U.S. Preventive Services Task Force gives prostate-specific antigen (PSA) screening a grade C recommendation for men aged 55 to 69, which means the decision should be an individual one made after a man weighs the benefits and harms against his own values. That grade exists because screening offers a small reduction in prostate cancer death while carrying a real risk of overdiagnosis and overtreatment. When a test can both help and harm in similar measure, the right choice depends on the person, not on a blanket rule.

What the grade C actually means

A USPSTF grade is not a verdict on whether a test works. It is a judgment about the size and certainty of the net benefit, meaning benefit minus harm. A grade A or B signals that the balance clearly favors offering the service. A grade D signals that the harms outweigh the benefits. A grade C sits deliberately in the middle: the net benefit is small, and reasonable people, informed of the same facts, will land in different places.

For PSA screening in men aged 55 to 69, the 2018 recommendation states that "the decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one." The Task Force adds that "before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision." For men 70 and older, the recommendation shifts to grade D: screening is recommended against, because the harms become more likely to outweigh a benefit that takes many years to appear.

That structure is the heart of the matter. The grade C is not a shrug. It is a specific claim that the evidence makes this a preference-sensitive decision.

The evidence behind the small benefit

The best evidence comes from large randomized trials. The European Randomized Study of Screening for Prostate Cancer (ERSPC) found that screening reduced prostate cancer mortality, and the benefit grew as follow-up lengthened. The most honest way to describe the magnitude is in concrete terms: the number of men who must be screened to prevent one prostate cancer death declined over time from roughly 1,410 to 781 with longer follow-up in that trial, and screening about 323 men prevented one case of metastatic disease. The USPSTF summarized the mortality effect as approximately 1.3 prostate cancer deaths prevented per 1,000 men screened over about 13 years.

The U.S. trial, the Prostate, Lung, Colorectal, and Ovarian (PLCO) study, initially showed no benefit, but its own investigators later described it as a comparison of organized versus opportunistic screening rather than screening versus none, because many men in the control group were tested anyway. That contamination limits how much weight the null result can bear. Taken together, the trials point to a benefit that is real but modest.

A benefit of this size is worth having if a man values it and accepts the trade-offs. It is not large enough to justify screening everyone by default.

The harms that make this preference-sensitive

The counterweight is overdiagnosis. Because many prostate cancers grow so slowly that they would never cause symptoms or shorten life, a screening test can find cancers that were never destined to matter. The USPSTF notes that follow-up of the large trials suggests 20 percent to 50 percent of screen-detected prostate cancers may be overdiagnosed. A man cannot know in advance whether his cancer falls in that group.

Overdiagnosis becomes harmful when it leads to overtreatment. Surgery and radiation carry meaningful risks of urinary incontinence and erectile dysfunction. The PIVOT trial found no overall survival benefit from surgery versus observation for many men with localized, lower-risk disease, which means some men accept those harms without gaining time.

The evidence also shows how this balance can improve. The harms of overtreatment are being reduced by the growing use of active surveillance, in which lower-risk cancers are monitored rather than treated immediately. That shift narrows the gap between a diagnosis and a harm, which is one reason the screening conversation looks different today than it did a decade ago.

How to think through the decision

A useful conversation covers a few points. First, a man's baseline risk matters, and family history and race can raise it. Second, life expectancy matters, because the mortality benefit takes more than a decade to appear, which is the logic behind recommending against screening after age 70. Third, values matter: some men want every chance to catch a cancer early and accept the risk of treating one that never needed treating, while others weigh the risk of incontinence or impotence more heavily and prefer to wait. None of these positions is wrong.

The USPSTF has also finalized a research plan to update this recommendation, so the evidence base is under active review. The 2018 grade C remains the current guidance as this is written.

This article is educational and not medical advice. The point is not to talk anyone into or out of a PSA test, but to show why the evidence hands this decision to the individual rather than settling it in advance.